MX2013015127A - Composicion y formulacion que comprende iduronato - 2 - sulfatasa humana recombinante y metodo de preparacion de la misma. - Google Patents

Composicion y formulacion que comprende iduronato - 2 - sulfatasa humana recombinante y metodo de preparacion de la misma.

Info

Publication number
MX2013015127A
MX2013015127A MX2013015127A MX2013015127A MX2013015127A MX 2013015127 A MX2013015127 A MX 2013015127A MX 2013015127 A MX2013015127 A MX 2013015127A MX 2013015127 A MX2013015127 A MX 2013015127A MX 2013015127 A MX2013015127 A MX 2013015127A
Authority
MX
Mexico
Prior art keywords
composition
sulfatase
formulation
preparation
recombinant human
Prior art date
Application number
MX2013015127A
Other languages
English (en)
Other versions
MX341946B (es
Inventor
Thong-Gyu Jin
Yo Kyung Chung
Sang Hoon Paik
Yoo Chang Park
Jinwook Seo
Yong Woon Choi
Jong Mun Son
Yong-Chul Kim
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46716009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013015127(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of MX2013015127A publication Critical patent/MX2013015127A/es
Publication of MX341946B publication Critical patent/MX341946B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe una composición que comprende iduronato-2-sulfatasa (IDS) recombinante. El patrón de glicosilación y contenido de formilglicina de la composición de IDS son diferentes de aquel de Elaprase y tienen eficacia farmacéutica superior y son más seguras que el agente convencional y por lo tanto, puede utilizarse efectivamente para la terapia del síndrome de Hunter.
MX2013015127A 2011-06-24 2012-06-15 Composicion y formulacion que comprende iduronato - 2 - sulfatasa humana recombinante y metodo de preparacion de la misma. MX341946B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161500994P 2011-06-24 2011-06-24
KR1020120012718A KR101158673B1 (ko) 2011-06-24 2012-02-08 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
PCT/KR2012/004734 WO2012177020A2 (en) 2011-06-24 2012-06-15 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

Publications (2)

Publication Number Publication Date
MX2013015127A true MX2013015127A (es) 2014-06-11
MX341946B MX341946B (es) 2016-09-08

Family

ID=46716009

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015127A MX341946B (es) 2011-06-24 2012-06-15 Composicion y formulacion que comprende iduronato - 2 - sulfatasa humana recombinante y metodo de preparacion de la misma.

Country Status (28)

Country Link
US (2) US9206402B2 (es)
EP (1) EP2723369B2 (es)
JP (2) JP5844459B2 (es)
KR (2) KR101158673B1 (es)
CN (1) CN103635203B (es)
AU (2) AU2012274215B2 (es)
BR (1) BR112013032193A2 (es)
CA (1) CA2839674C (es)
CO (1) CO6862105A2 (es)
CY (1) CY1117861T1 (es)
DK (1) DK2723369T4 (es)
EA (1) EA026499B1 (es)
ES (1) ES2575377T5 (es)
FI (1) FI2723369T4 (es)
HK (1) HK1195731A1 (es)
HR (1) HRP20160490T4 (es)
HU (1) HUE027431T2 (es)
IL (1) IL230120B (es)
MX (1) MX341946B (es)
MY (1) MY166647A (es)
PE (1) PE20140734A1 (es)
PL (1) PL2723369T5 (es)
PT (1) PT2723369E (es)
RS (1) RS54822B2 (es)
SI (1) SI2723369T2 (es)
SM (1) SMT201600194B (es)
UA (1) UA109949C2 (es)
WO (1) WO2012177020A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
CN106153746B (zh) * 2015-03-31 2020-11-06 三生国健药业(上海)股份有限公司 IgG2型单抗二硫键配对分析方法
CN106153745B (zh) * 2015-03-31 2020-11-10 三生国健药业(上海)股份有限公司 抗体蛋白二硫键配对分析方法
CN106153744B (zh) * 2015-03-31 2020-11-10 三生国健药业(上海)股份有限公司 融合蛋白二硫键配对分析方法
KR20170004814A (ko) 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
WO2017003270A1 (ko) * 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
SG11201805598WA (en) * 2015-12-30 2018-07-30 Green Cross Corp Methods and compositions for treating hunter syndrome
SG11201806335RA (en) * 2016-02-22 2018-09-27 Agency Science Tech & Res Cell culture medium
BR112019021569A2 (pt) 2017-04-14 2020-05-12 Regenxbio Inc. Precursor de iduronato-2-sulfatase humana recombinante glicosilada (ids), método para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
WO2019022563A2 (ko) * 2017-07-28 2019-01-31 한미약품 주식회사 이두로네이트 2-설파타제 결합체
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
KR102671857B1 (ko) 2018-05-30 2024-06-04 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
EP3846780A4 (en) * 2018-09-05 2022-11-30 Sangamo Therapeutics, Inc. ENZYMATIC TESTS FOR QUANTIFICATION OF THERAPY IN PATIENTS WITH MUCOPOLYSACCHARIDOSE TYPE I OR II
US11857641B2 (en) 2019-02-06 2024-01-02 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type I
EP4291249A2 (en) 2021-02-10 2023-12-20 RegenxBio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
WO2024144003A1 (ko) * 2022-12-29 2024-07-04 주식회사 녹십자 뮤코다당질 축적증에서의 안면 이형의 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US8227212B2 (en) * 2003-02-11 2012-07-24 Shire Human Genetic Therapies, Inc. Cell that expresses a sulfatase and a formylglycine generating enzyme
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제

Also Published As

Publication number Publication date
JP5844459B2 (ja) 2016-01-20
IL230120B (en) 2020-09-30
HK1195731A1 (zh) 2014-11-21
SI2723369T1 (sl) 2016-09-30
CY1117861T1 (el) 2017-05-17
UA109949C2 (uk) 2015-10-26
NZ620284A (en) 2015-11-27
JP6000432B2 (ja) 2016-09-28
ES2575377T3 (es) 2016-06-28
US9249397B2 (en) 2016-02-02
EP2723369A2 (en) 2014-04-30
EP2723369A4 (en) 2014-12-24
KR101910124B1 (ko) 2018-10-19
EP2723369B2 (en) 2023-05-10
ES2575377T5 (es) 2023-10-26
SMT201600194B (it) 2016-08-31
US9206402B2 (en) 2015-12-08
PL2723369T3 (pl) 2016-09-30
RS54822B2 (sr) 2023-09-29
CO6862105A2 (es) 2014-02-10
RS54822B1 (sr) 2016-10-31
WO2012177020A2 (en) 2012-12-27
JP2016056179A (ja) 2016-04-21
JP2014520143A (ja) 2014-08-21
WO2012177020A9 (en) 2013-02-14
AU2016201487B2 (en) 2017-10-19
BR112013032193A2 (pt) 2017-11-21
HUE027431T2 (en) 2016-09-28
US20150320843A1 (en) 2015-11-12
CN103635203B (zh) 2016-06-08
EP2723369B1 (en) 2016-04-13
SI2723369T2 (sl) 2023-08-31
AU2016201487A1 (en) 2016-03-24
HRP20160490T4 (hr) 2023-09-15
PT2723369E (pt) 2016-06-03
KR20160030591A (ko) 2016-03-21
AU2012274215A1 (en) 2014-02-20
CA2839674C (en) 2018-04-24
KR101158673B1 (ko) 2012-07-03
AU2012274215B2 (en) 2015-12-10
HRP20160490T1 (hr) 2016-08-12
PL2723369T5 (pl) 2024-02-05
EA026499B1 (ru) 2017-04-28
DK2723369T3 (en) 2016-06-13
MY166647A (en) 2018-07-18
CN103635203A (zh) 2014-03-12
US20140242059A1 (en) 2014-08-28
CA2839674A1 (en) 2012-12-27
FI2723369T4 (fi) 2023-08-31
EA201490149A1 (ru) 2014-09-30
DK2723369T4 (da) 2023-07-24
WO2012177020A3 (en) 2013-04-04
MX341946B (es) 2016-09-08
PE20140734A1 (es) 2014-07-04

Similar Documents

Publication Publication Date Title
MX2013015127A (es) Composicion y formulacion que comprende iduronato - 2 - sulfatasa humana recombinante y metodo de preparacion de la misma.
MY179703A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
WO2013090278A3 (en) Intranasal dexmedetomidine compositions and methods of use thereof
ZA200810124B (en) Pharmaceutical combination comprising 3-(3-dimethyl-amino-1-ethyl-2-methyl-propyl)-phenol and Paracetamol
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
MD20140131A2 (ro) Doză şi formă preparativă nouă pentru inhalare care cuprinde aclidiniu
MX368184B (es) Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación.
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
WO2011076840A3 (en) Aerosol formulation for copd
IN2014MN02156A (es)
WO2012030308A3 (en) Formulation comprising cellobiose
EP2886112A4 (en) COMPOSITION CONTAINING AS ACTIVE INGREDIENT OF S-ALLYL-L-CYSTEINE FOR PREVENTING OR TREATING OCULAR DISEASES, AND PHARMACEUTICAL FORMULATION COMPRISING THE SAME
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
EP2875823A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHIES CONTAINING HENOSIS STAPF EXTRACT FROM VAR. MUNRO OF PHYLLOSTACHYS NIGRA AS ACTIVE INGREDIENT
HK1216253A1 (zh) 新型化合物、其藥學上可接受的鹽或光學異構體、用於製備它們的方法以及包含它們作為有效成分的用於預防或治療病毒性疾病的藥物組合物
WO2015130963A3 (en) Compositions and methods for administering insulin or insulin-like protein to the brain
CA2865484A1 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
UA97044C2 (ru) Средство противовирусной и иммуностимулирующей активности, способ получения средства противовирусной и иммуностимулирующей активности, способ профилактики и лечения инфекционных болезней
WO2011121475A3 (en) Modified release dosage form comprising desvenlafaxine or salts thereof

Legal Events

Date Code Title Description
FG Grant or registration